These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 32876736)

  • 1. Early C-reactive protein kinetics predict survival of patients with advanced urothelial cancer treated with pembrolizumab.
    Kijima T; Yamamoto H; Saito K; Kusuhara S; Yoshida S; Yokoyama M; Matsuoka Y; Numao N; Sakai Y; Matsubara N; Yuasa T; Masuda H; Yonese J; Kageyama Y; Fujii Y
    Cancer Immunol Immunother; 2021 Mar; 70(3):657-665. PubMed ID: 32876736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. C-reactive Protein Is a Prognostic Factor for Survival in Metastatic Upper Tract Urothelial Carcinoma Patients Receiving Pembrolizumab.
    Nagasaka H; Yamamoto S; Suzuki A; Usui K; Terao H; Nakaigawa N; Kishida T
    In Vivo; 2024; 38(4):1823-1828. PubMed ID: 38936923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of C-reactive Protein Flare Response in Patients With Advanced Urothelial Carcinoma Who Received Pembrolizumab.
    Tomisaki I; Harada M; Tokutsu K; Minato A; Nagata Y; Kimuro R; Matsumoto M; Fujimoto N
    In Vivo; 2021; 35(6):3563-3568. PubMed ID: 34697195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pembrolizumab in the treatment of advanced urothelial cancer.
    Lundgren KT; Farina MS; Bellmunt J
    Future Oncol; 2017 Dec; 13(30):2745-2758. PubMed ID: 29219016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic outcomes and safety in patients treated with pembrolizumab for advanced urothelial carcinoma: experience in real-world clinical practice.
    Tamura D; Jinnouchi N; Abe M; Ikarashi D; Matsuura T; Kato R; Maekawa S; Kato Y; Kanehira M; Takata R; Obara W
    Int J Clin Oncol; 2020 May; 25(5):899-905. PubMed ID: 31907720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expressions of PD-L1 and Nectin-4 in urothelial cancer patients treated with pembrolizumab.
    Ueki H; Hinata N; Kitagawa K; Hara T; Terakawa T; Furukawa J; Harada K; Nakano Y; Komatsu M; Fujisawa M; Shirakawa T
    Clin Transl Oncol; 2022 Mar; 24(3):568-577. PubMed ID: 34687441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status.
    Grivas P; Plimack ER; Balar AV; Castellano D; O'Donnell PH; Bellmunt J; Powles T; Hahn NM; de Wit R; Bajorin DF; Ellison MC; Frenkl TL; Godwin JL; Vuky J
    Eur Urol Oncol; 2020 Jun; 3(3):351-359. PubMed ID: 32423837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early response of C-reactive protein as a predictor of survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors.
    Yasuda Y; Saito K; Yuasa T; Uehara S; Kawamura N; Yokoyama M; Ishioka J; Matsuoka Y; Yamamoto S; Okuno T; Yonese J; Kihara K; Fujii Y
    Int J Clin Oncol; 2017 Dec; 22(6):1081-1086. PubMed ID: 28733795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of C-reactive protein kinetics on survival of patients with advanced urothelial carcinoma treated by second-line chemotherapy with gemcitabine, etoposide and cisplatin.
    Saito K; Urakami S; Komai Y; Yasuda Y; Kubo Y; Kitsukawa S; Okubo Y; Yamamoto S; Yonese J; Fukui I
    BJU Int; 2012 Nov; 110(10):1478-84. PubMed ID: 22520732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Antacids on the Survival of Patients With Metastatic Urothelial Carcinoma Treated With Pembrolizumab.
    Sekito T; Bekku K; Katayama S; Watanabe T; Tsuboi I; Yoshinaga K; Maruyama Y; Yamanoi T; Kawada T; Tominaga Y; Sadahira T; Iwata T; Nishimura S; Kusumi N; Edamura K; Kobayashi T; Kurose K; Ichikawa T; Miyaji Y; Wada K; Kobayashi Y; Araki M
    Clin Genitourin Cancer; 2024 Aug; 22(4):102097. PubMed ID: 38763123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Immune-Related Adverse Events with Pembrolizumab Efficacy in the Treatment of Advanced Urothelial Carcinoma.
    Kobayashi K; Suzuki K; Hiraide M; Aoyama T; Yokokawa T; Shikibu S; Hashimoto K; Iikura Y; Sato H; Sugiyama E; Tajima M; Hama T
    Oncology; 2020; 98(4):237-242. PubMed ID: 31935736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of C-reactive protein flare-response on oncological outcomes in patients with metastatic renal cell carcinoma treated with nivolumab.
    Fukuda S; Saito K; Yasuda Y; Kijima T; Yoshida S; Yokoyama M; Ishioka J; Matsuoka Y; Kageyama Y; Fujii Y
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33602695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pembrolizumab in Patients with Advanced Urothelial Carcinoma with ECOG Performance Status 2: A Real-World Study from the ARON-2 Project.
    Rizzo A; Monteiro FSM; Ürün Y; Massari F; Park SH; Bourlon MT; Poprach A; Rizzo M; Takeshita H; Giannatempo P; Soares A; Roviello G; Molina-Cerrillo J; Carrozza F; Abahssain H; Messina C; Kopp RM; Pichler R; Formisano L; Tural D; Atzori F; Calabrò F; Kanesvaran R; Buti S; Santoni M
    Target Oncol; 2024 Sep; 19(5):747-755. PubMed ID: 39107651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based Therapy.
    Patterson K; Prabhu V; Xu R; Li H; Meng Y; Zarabi N; Zhong Y; Batteson R; Pellissier J; Keefe S; Grivas P; de Wit R
    Eur Urol Oncol; 2019 Sep; 2(5):565-571. PubMed ID: 31412011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk stratification for the prognosis of patients with chemoresistant urothelial cancer treated with pembrolizumab.
    Kobayashi T; Ito K; Kojima T; Kato M; Kanda S; Hatakeyama S; Matsui Y; Matsushita Y; Naito S; Shiga M; Miyake M; Muro Y; Nakanishi S; Kato Y; Shibuya T; Hayashi T; Yasumoto H; Yoshida T; Uemura M; Taoka R; Kamiyama M; Ogawa O; Kitamura H; Nishiyama H;
    Cancer Sci; 2021 Feb; 112(2):760-773. PubMed ID: 33283385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pembrolizumab for advanced urothelial carcinoma: exploratory ctDNA biomarker analyses of the KEYNOTE-361 phase 3 trial.
    Powles T; Chang YH; Yamamoto Y; Munoz J; Reyes-Cosmelli F; Peer A; Cohen G; Yu EY; Lorch A; Bavle A; Homet Moreno B; Markensohn J; Edmondson M; Chen C; Cristescu R; Peña C; Lunceford J; Gunduz S
    Nat Med; 2024 Sep; 30(9):2508-2516. PubMed ID: 38823511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initial Experience of Pembrolizumab Therapy in Japanese Patients With Metastatic Urothelial Cancer.
    Yasuoka S; Yuasa T; Nishimura N; Ogawa M; Komai Y; Numao N; Yamamoto S; Kondo Y; Yonese J
    Anticancer Res; 2019 Jul; 39(7):3887-3892. PubMed ID: 31262917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Performance Status With Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy.
    Sehgal K; Gill RR; Widick P; Bindal P; McDonald DC; Shea M; Rangachari D; Costa DB
    JAMA Netw Open; 2021 Feb; 4(2):e2037120. PubMed ID: 33570575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial.
    Nishiyama H; Yamamoto Y; Sassa N; Nishimura K; Fujimoto K; Fukasawa S; Yokoyama M; Enokida H; Takahashi K; Tanaka Y; Imai K; Shimamoto T; Perini R; Frenkl T; Bajorin D; Bellmunt J
    Int J Clin Oncol; 2020 Jan; 25(1):165-174. PubMed ID: 31729625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pembrolizumab Combined With Either Docetaxel or Gemcitabine in Patients With Advanced or Metastatic Platinum-Refractory Urothelial Cancer: Results From a Phase I Study.
    Parikh M; Pan CX; Beckett LA; Li Y; Robles DA; Aujla PK; Lara PN
    Clin Genitourin Cancer; 2018 Dec; 16(6):421-428.e1. PubMed ID: 30166228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.